文献速递泌尿男性生殖肿瘤

年轻前列腺癌患者质子放疗、SBRT与IMRT的毒性与费用比较

Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer.
PubMed 文献 · J Clin Oncol · 2018-03-21

该研究基于MarketScan商业保险数据库,纳入2008至2015年接受放疗的65岁以下前列腺癌男性,采用倾向评分匹配比较质子治疗、立体定向体部放疗(SBRT)与调强放疗(IMRT)的毒性和费用。质子治疗泌尿毒性和勃起功能障碍风险低于IMRT,但肠道毒性更高且费用近两倍;SBRT与IMRT毒性谱相似,费用略低。

要点

  • 质子治疗较IMRT泌尿毒性和勃起功能障碍更低,但肠道毒性更高、费用近两倍。
  • SBRT与IMRT的泌尿、肠道及勃起功能障碍毒性无显著差异。
  • SBRT费用略低于IMRT,但泌尿瘘风险高于IMRT。

核心结论

  • 在年轻前列腺癌男性中,质子放疗与泌尿毒性显著降低相关,但肠道毒性增加,费用接近IMRT的两倍。
  • SBRT与IMRT毒性谱相似,SBRT费用略低于IMRT。

研究设计与样本

  • 使用MarketScan Commercial Claims and Encounters数据库,识别2008至2015年间接受放疗的前列腺癌男性。
  • 693例质子治疗患者按临床和社会人口学因素倾向评分匹配至3,465例IMRT患者。
  • 310例SBRT患者倾向评分匹配至3,100例IMRT患者。
  • 采用比例风险模型比较泌尿、肠道和勃起功能障碍毒性的累积发生率,费用从支付方角度按2015年美元计算。

主要发现

  • 质子治疗患者2年复合泌尿毒性为33%对42%(P < .001),勃起功能障碍为21%对28%(P < .001),均低于IMRT。
  • 质子治疗患者2年肠道毒性为20%对15%(P = .02),高于IMRT。
  • 质子治疗平均放疗费用为$115,501,IMRT为$59,012(P < .001)。
  • SBRT与IMRT在复合泌尿、肠道及勃起功能障碍毒性上无显著差异(P > .05)。
  • SBRT 2年泌尿瘘风险为1%对0.1%(P = .009),高于IMRT;SBRT平均费用$49,504,IMRT $57,244(P < .001)。

关键数值与推荐

  • 质子治疗2年复合泌尿毒性33%对42%(P < .001),勃起功能障碍21%对28%(P < .001),肠道毒性20%对15%(P = .02)。
  • 质子治疗平均放疗费用$115,501,IMRT $59,012(P < .001)。
  • SBRT与IMRT各毒性比较P > .05;SBRT 2年泌尿瘘1%对0.1%(P = .009)。
  • SBRT平均放疗费用$49,504,IMRT $57,244(P < .001)。

临床怎么用

  • 年轻前列腺癌患者选择质子治疗时需权衡泌尿毒性降低与肠道毒性增加及更高费用。
  • SBRT可作为与IMRT毒性相近且费用略低的选项,但需关注泌尿瘘风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose To compare the toxicities and cost of proton radiation and stereotactic body radiotherapy (SBRT) with intensity-modulated radiotherapy (IMRT) for prostate cancer among men younger than 65 years of age with private insurance. Methods Using the MarketScan Commercial Claims and Encounters database, we identified men who received radiation for prostate cancer between 2008 and 2015. Patients undergoing proton therapy and SBRT were propensity score-matched to IMRT patients on the basis of clinical and sociodemographic factors. Proportional hazards models compared the cumulative incidence of urinary, bowel, and erectile dysfunction toxicities by treatment. Cost from a payer's perspective was calculated from claims and adjusted to 2015 dollars. Results A total of 693 proton therapy patients were matched to 3,465 IMRT patients. Proton therapy patients had a lower risk of composite urinary toxicity (33% v 42% at 2 years; P < .001) and erectile dysfunction (21% v 28% at 2 years; P < .001), but a higher risk of bowel toxicity (20% v 15% at 2 years; P = .02). Mean radiation cost was $115,501 for proton therapy patients and $59,012 for IMRT patients ( P < .001). A total of 310 SBRT patients were matched to 3,100 IMRT patients. There were no significant differences in composite urinary, bowel, or erectile dysfunction toxicities between SBRT and IMRT patients ( P > .05), although a higher risk of urinary fistula was noted with SBRT (1% v 0.1% at 2 years; P = .009). Mean radiation cost for SBRT was $49,504 and $57,244 for IMRT ( P < .001). Conclusion Among younger men with prostate cancer, proton radiation was associated with significant reductions in urinary toxicity but increased bowel toxicity at nearly twice the cost of IMRT. SBRT and IMRT were associated with similar toxicity profiles; SBRT was modestly less expensive than IMRT.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Pan HY, Jiang J, Hoffman KE, et al. Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer. J Clin Oncol. 2018. PMID: 29561693. doi:10.1200/JCO.2017.75.5371

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。